Pharma Biotech & Nutrition

Our Offerings

As the world’s largest company for contract development and manufacturing, our Pharma Biotech & Nutrition segment is recognized for its reliable, high-quality services, regulatory track record, global footprint, innovative technology platforms and extensive experience.

Our vision is to enable our customers to meet some of the greatest challenges in patient treatment. Our broad capabilities span across biologics, small molecules (including highly potent active pharmaceutical ingredients such as cytotoxins), bioconjugates, cell and gene technology, and live biotherapeutics. We manage projects from pre-clinical stage through to commercialization, from established therapeutics to advanced personalized medicines, and our expertise covers both drug substance and drug product.

>730

Preclinical and Clinical Small1 and Large2 Molecules

>310

Commercial Small1 and Large3 Molecules

>200

Billion Capsules Produced4

1 Including active pharmaceutical ingredients (API), highly potent API (HPAPI) and dosage form and delivery systems

2 Including mammalian and microbial, cell & gene therapy products, applied protein services and drug product services

3 Including mammalian and microbial and cell & gene therapy products

4 Including pharma and nutritional hard capsules

In February 2019, we changed our structure, combining Pharma & Biotech and Consumer Health & Nutrition into the Lonza Pharma Biotech & Nutrition (LPBN) segment. With this structure, we can leverage our innovation programs and technology platforms across the nutrition-pharma spectrum, most importantly in the pharma and nutritional capsules businesses.

In 2019, the LPBN segment comprised the following offerings:

CDMO service businesses:

Product businesses:

Personal Perspectives

Our Global Footprint

With 37 sites across three continents and 11,148 employees, we capitalize on our global footprint and have the flexibility to address regional and even local marketplace needs.

Portsmouth, USA

Mammalian

  • Commercial manufacturing

Hayward, USA

Mammalian

  • Clinical manufacturing

Visp, Switzerland

Bioconjugates

  • Clinical development & manufacturing
  • Commercial manufacturing

Mammalian2

  • Clinical development & manufacturing
  • Commercial manufacturing

Microbial

  • Clinical development & manufacturing
  • Commercial manufacturing

Basel/Stein, Switzerland

Drug product services

  • Clinical & commercial development
  • Clinical & commercial manufacturing1

Cambridge, UK

Pre-clinical candidate risk assessment

  • Manufacturability & immunogenicity
  • Non-GMP research product supply

Slough, UK

Mammalian

  • Clinical development & manufacturing

Porriño, Spain

Mammalian

  • Commercial manufacturing

Guangzhou, China2

Mammalian

  • Clinical development & manufacturing

Tuas, Singapore

Mammalian

  • Clinical development & manufacturing
  • Commercial manufacturing

1 cGMP Sterile manufacturing

2 Capabilities to become available from 2020

Portsmouth, USA

Cell & gene technologies

  • Clinical & commercial manufacturing

Houston, USA (including El Rio)3

Cell & gene technologies (including viral vector manufacturing)

  • Clinical & commercial development & manufacturing

Kingston, Canada

Cell & gene technologies

  • Clinical development

Geleen, Netherlands (including Maastricht)3

Cell & gene technologies

  • Clinical & commercial development & manufacturing

Tuas, Singapore

Cell & gene technologies

  • Clinical development & manufacturing

Tokyo, Japan4

Cell & gene technologies

  • Clinical & commercial development & manufacturing

3 Locations connected to another site

4 Facility owned and operated by Nikon CeLL innovation Co. Ltd. under Nikon-Lonza partnership

Quakertown, USA

Particle engineering and drug products

  • Dosage forms & delivery solutions

Tampa, USA

Particle engineering and drug products

  • Dosage forms & delivery solutions

Bend, USA

Particle engineering and drug products

  • Dosage forms & delivery solutions

Visp, Switzerland

Drug substance

  • API development & manufacturing

Monteggio, Switzerland

Particle engineering and drug products

  • Dosage forms & delivery solutions

Ploermel, France

Particle engineering and drug product

  • Dosage forms & delivery solutions

Edinburgh, UK

Particle engineering and drug products

  • Dosage forms & delivery solutions

Nansha, China

Drug substance

  • API development & manufacturing

Greenwood, USA

Pharma & nutritional capsules

Puebla, Mexico

Nutritional capsules

Colmar, France

Pharma & nutritional capsules

Bornem, Belgium (including Komec Helsen)

Pharma & nutritional capsules

Sagamihara, Japan

Pharma & nutritional capsules

Suzhou, China

Pharma & nutritional capsules

Jakarta, Indonesia

Pharma & nutritional capsules

Haryana, India

Pharma & nutritional capsules

Benicia, USA

Nutritional ingredients

Cohasset, USA

Nutritional ingredients

Fort Smith, USA

Nutritional ingredients

Nansha, China

Nutritional ingredients

Walkersville, USA (including Wayne and Salisbury)3

Bioscience

Durham, USA

Bioscience

Rockland, USA

Bioscience

Verviers, Belgium

Bioscience

Cologne, Germany

Bioscience

Copenhagen, Denmark

Bioscience

3Locations connected to another site

Financial Highlights

Lonza Pharma Biotech & Nutrition (LPBN) achieved continued double-digit sales growth above guidance for 2019. The realigned segment includes the nutritional hard capsules business (acquired with Capsugel), as well as a small portfolio of nutritional ingredients and formulation services. We delivered CHF 4.2 billion sales in full-year 2019 and a CORE EBITDA of CHF 1.4 billion while investing in strategic growth projects, a number of which are expected to commence operations from the end of 2020.

Pharma Biotech & Nutrition

Million CHF

2019

Change in %

2018 Restated1

Sales

4,167

11.0

3,755

CORE EBITDA

1,371

10.0

1,246

Margin in %

32.9

 

33.2

CORE EBITDA excl. IFRS 16

1,347

8.1

1,246

Margin in %

32.3

 

33.2

CORE result from operating activities (EBIT)

1,125

10.3

1,020

Margin in %

27.0

 

27.2

CORE result from operating activities (EBIT) excl. IFRS 16

1,123

10.1

1,020

Margin in %

26.9

 

27.2

1

Restated to reflect the 2019 realignment of Lonza’s segments into Pharma Biotech & Nutrition and Specialty Ingredients

Sales

Million CHF

Sales Lonza Pharma Biotech & Nutrition (bar chart)
CORE EBITDA

Million CHF

CORE EBITDA Margin

In %

CORE EBITDA and CORE EBITDA Margin Lonza Pharma Biotech & Nutrition (bar chart)

1 Reported pro-forma full-year 2017 financial results include Capsugel full-year 2017 financial results

2 Restated to reflect the 2019 realignment of Lonza’s segments into Pharma Biotech & Nutrition and Specialty Ingredients

(PDF:) Download section PDF Segments Download Center All documents and tables